MannKind FY2026 EPS Forecast Decreased by Leerink Partnrs

MannKind Corporation (NASDAQ:MNKD - Free Report) - Stock analysts at Leerink Partnrs cut their FY2026 earnings estimates for shares of MannKind in a research note issued to investors on Wednesday, June 18th. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical company will post earnings of $0.14 per share for the year, down from their previous estimate of $0.16. The consensus estimate for MannKind's current full-year earnings is $0.10 per share.

MannKind (NASDAQ:MNKD - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.01. The business had revenue of $78.35 million during the quarter, compared to the consensus estimate of $75.86 million. MannKind had a negative return on equity of 32.41% and a net margin of 10.12%. The company's revenue for the quarter was up 18.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.05 EPS.

MNKD has been the topic of several other reports. Wall Street Zen upgraded shares of MannKind from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Wedbush reaffirmed an "outperform" rating and set a $11.00 price target on shares of MannKind in a research note on Thursday, February 27th. Finally, Mizuho initiated coverage on MannKind in a research note on Thursday, April 10th. They issued an "outperform" rating and a $12.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $10.33.

MannKind Trading Up 1.6%

MNKD stock opened at $3.81 on Thursday. The company's 50-day moving average price is $4.43 and its 200 day moving average price is $5.31. The company has a market cap of $1.16 billion, a P/E ratio of 38.10 and a beta of 1.02. MannKind has a 52 week low of $3.63 and a 52 week high of $7.63.

Institutional Trading of MannKind

Several hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new stake in MannKind in the 4th quarter valued at about $37,000. Jones Financial Companies Lllp raised its holdings in shares of MannKind by 3,294.8% in the 4th quarter. Jones Financial Companies Lllp now owns 6,586 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 6,392 shares in the last quarter. Kovitz Investment Group Partners LLC bought a new position in shares of MannKind in the fourth quarter valued at $65,000. Blueshift Asset Management LLC purchased a new stake in shares of MannKind during the first quarter valued at $51,000. Finally, Beirne Wealth Consulting Services LLC acquired a new position in shares of MannKind in the fourth quarter worth about $66,000. Institutional investors own 49.55% of the company's stock.

Insider Buying and Selling at MannKind

In other MannKind news, Director Steven B. Binder sold 12,078 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $4.40, for a total transaction of $53,143.20. Following the completion of the sale, the director now owns 989,343 shares in the company, valued at $4,353,109.20. The trade was a 1.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David Thomson sold 32,179 shares of the stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $4.68, for a total transaction of $150,597.72. Following the sale, the executive vice president now owns 772,427 shares in the company, valued at approximately $3,614,958.36. This trade represents a 4.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 190,831 shares of company stock valued at $846,298 in the last ninety days. Insiders own 2.70% of the company's stock.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.